PatientsVille.com Logo


Carbatrol Medical Research Studies

Up-to-date List of Carbatrol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Carbatrol Medical Research Studies

Rank Status Study
1 Recruiting Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
Conditions: Alpha-1-antitrypsin Deficiency;   Liver Cirrhosis
Interventions: Drug: Drug-Carbamazepine (Tegretol XR);   Drug: Carbamazepine (Tegretol XR) Placebo
Outcome Measures: The primary outcome will be to determine the effect of Carbamazepine on hepatic ATZ load.;   For the secondary outcomes we will determine the effect of Carbamazepine treatment on hepatic fibrosis.;   For the secondary outcome we will determine if Carbamazepine treatment reduces the MELD score.
2 Recruiting Fed Bioequivalence Study of CBZ Formulations
Conditions: Bio-equivalence Study;   Fed Conditions
Interventions: Drug: Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose;   Drug: Tegretol CR 400 Single Dose-Auration CR 400 Single Dose
Outcome Measures: AUC0-240;   AUC0-inf;   Cmax;   AE
3 Recruiting Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older
Conditions: Epilepsy;   Monotherapy
Interventions: Drug: Lacosamide;   Drug: Carbamazepine-Controlled Release (CBZ-CR)
Outcome Measures: Number of subjects with at least one treatment-emergent Adverse Event (AE) during the Treatment Phase (Maximum of 3.5 Years);   Number of subjects who withdrew from the study due to a treatment-emergent Adverse Event (AE) during the Treatment Phase (Maximum 3.5 Years);   Number of subjects with at least one treatment- emergent Serious Adverse Event (SAE) during the Treatment Phase (Maximum of 3.5 years)
4 Unknown  Compare the Efficacy of Acupuncture Therapy and Carbamazepine Oral Dosage in Patients With Carpal Tunnel Syndrome by Multiple Excitability Test
Conditions: Carpal Tunnel Syndrome;   Multiple Excitability Test
Interventions: Drug: Carbamazepine;   Procedure: Acupuncture
Outcome Measures: Use QtracW and NCS to evaluate the changes between pre-treatment and post-treatment in patients in both arms.;   use BCTQ to evaluate the efficacy of 2 arms at week 4 and at week 12.;   use VAS to evaluate the efficacy of 2 arms at week 5, 8 and 12.;   Use Quality of Life questionnaire to compare the efficacy of 2 arms at week 12.;   Evaluate the safety of 2 arms during the study period
5 Recruiting Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures
Conditions: Epilepsy;   Partial Seizures
Interventions: Drug: Levetiracetam;   Drug: Carbamazepine
Outcome Measures: Proportion of subjects remaining seizure free during the 6-months Evaluation Period;   Proportion of subjects retained in the study for the duration of the period covering the Up Titration Period, Stabilization Period, and Evaluation Period;   Time to first seizure or discontinuation due to an Adverse Event (AE) / Lack of Efficacy (LOE) during the Evaluation Period;   Time to first seizure during the Evaluation Period;   Time to first seizure during the period covering the Up Titration Period, Stabilization Period, and Evaluation Period from the first dose of study drug
6 Unknown  Efficacy and Safety Evaluation of Carbamazepine for Prevention of Chemotherapy-induced Nausea and Vomiting
Condition: Chemotherapy-induced Nausea and Vomiting
Intervention: Drug: Carbamazepine
Outcome Measures: Efficacy of Carbamazepine;   Safety of Carbamazepine
7 Unknown  Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis
Conditions: Epileptic Seizures;   Stroke
Interventions: Drug: Levetiracetam;   Drug: Carbamazepine
Outcome Measures: number of patients free from post stroke recurrent crisis;   To compare retention time of LEV vs CBZ since first intake throughout treatment period;   To compare time to second seizure in both treatments.;   To evaluate differences in cognitive function and in quality of life in levetiracetam and carbamazepine patients having post-stroke seizures at the end of treatment period;   evaluate EEG changes as compared with baseline with that obtained at the end of treatment period;   To compare seizure frequency in levetiracetam and carbamazepine groups throughout treatment period;   To evaluate the safety of levetiracetam versus carbamazepine throughout the treatment period
8 Unknown  The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy
Condition: Epilepsy
Interventions: Drug: lamotrigine+valproate;   Drug: carbamazepine
Outcome Measure: Retention rate
9 Unknown  Premenstrual Dysphoric Disorder and Antiepileptic Drugs
Condition: Epilepsy
Outcome Measure: To determine if the frequency of premenstrual dysphoric disorder differs among antiepileptic drug monotherapies.
10 Not yet recruiting Urine Drug Levels Related to Source of Water for Irrigation for Vegetable Crops Among Healthy Israeli Volunteers
Condition: Healthy Individuals
Interventions: Other: vegetables from fresh or recycled water;   Other: receives vegetables from fresh water or recycled waste water farms
Outcome Measure: mean urine carbamazepine level in parts per billion
11 Recruiting Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures
Condition: Epilepsy
Intervention: Drug: Eslicarbazepine acetate (BIA 2-093)
Outcome Measures: The primary efficacy variable will be the proportion of subjects in the PP set who are seizure free for the entire 26-week Evaluation Period at the last received dose level.;   Proportion of subjects in the ITT set without a seizure during the 26-week Evaluation Period at the last evaluated dose.;   Proportion of subjects without a seizure during the 26-week Evaluation Period at the last evaluated dose.;   Proportion of seizure-free subjects during 1 year of treatment at the last evaluated dose, where the end of the 1-year period is defined as the same start date as for the 26-week evaluation +365 days.;   Time to first seizure at the last evaluated dose set.;   QOLIE-31 and Bond-Lader VAS;   Treatment retention time at the last evaluated dose;   Time to treatment failure at the first evaluated dose;   seizure freedom;   Adverse Event monitoring
12 Unknown  The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor
Conditions: Multiple Sclerosis;   Tremor
Intervention: Drug: Botulinum Toxin Type A
Outcome Measures: A decrease in tremor;   The safety profile of Botulinum Toxin in MS patients
13 Not yet recruiting Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012
Condition: Nodding Syndrome
Interventions: Drug: Pyridoxine;   Drug: Sodium Valproate;   Drug: Phenytoin;   Drug: Placebo
Outcome Measure: Change in the frequency of observed head nodding and other seizure activity from baseline (which is the frequency at week 1)
14 Recruiting Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
Condition: Bipolar Disorder
Interventions: Drug: Lithium;   Drug: Valproate;   Drug: Oxcarbazepine;   Drug: Quetiapine;   Drug: Olanzapine;   Drug: Ziprasidone
Outcome Measures: Change from baseline in Young Mania Rating Scale at 2 weeks and 6 weeks;   rate of dropout (treatment discontinuation);   Clinical Global Impressions (CGI) Scale;   Brief Psychiatric Rating Scale;   Global Assessment Scale;   Treatment Emergent Symptom Scale;   Hamilton Anxiety Rating Scale;   Hamilton Depression Rating Scale
15 Recruiting Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment
Condition: Epilepsy
Outcome Measures: Retention rate of topiramate, levetiracetam and oxcarbazepine during 24 months of treatment;   Evaluate the confounding factors affecting the retention rate;   Evaluate the response rate through seizure reduction (≥75%, ≥50%) in 2-year treatment with each antiepileptic drugs (topiramate, levetiracetam, oxcarbazepine)
16 Not yet recruiting Protective Role of Oxcarbazepine in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Oxcarbazepine;   Drug: Placebo
Outcome Measures: Relative reduction of CSF neurofilament light chain levels;   Safety of Oxcarbazepine in multiple sclerosis patients;   Relative reduction of CSF neurofilament levels;   Change in clinical outcome measured by neurological examination.;   Change in clinical outcome measured by cognitive assessment;   Change in patient reported outcomes measured by questionnaires
17 Recruiting Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
Condition: Cancer
Interventions: Drug: Morphine;   Drug: Oxcarbazepine
Outcome Measures: Number of patients with adverse events as a measure of safety and toxicity;   Changes in Pain control;   Changes in Consumption;   Changes in Quality of Life
18 Recruiting Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
Conditions: Epilepsy, Partial;   Epilepsy, Localization Related;   Adverse Effects
Interventions: Drug: Oxcarbazepine;   Drug: levetiracetam;   Drug: lamotrigine
Outcome Measures: Conners' Continuous Performance Test (CPT) Confidence Interval;   Child Behavior Checklist

These studies may lead to new treatments and are adding insight into Carbatrol etiology and treatment.

A major focus of Carbatrol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Carbatrol